Fig. 4: Persistence of Sino 19 cell and B-cell aplasia.

a Panel shows the results of Sino 19 cells detected by qRT-PCR in peripheral blood samples. The first negative was defined as the time of first negative measurement by qRT-PCR. The median persistence time of Sino 19 cells for all patients who attained CR/CRi was 85 days (range 44–498 days), excluding 10 patients that were bridged to allo-HSCT. 15 (78.9%) patients relapsed after the Sino 19 cell loss or at the same time; another 4 (21.1%) relapsed under the state of Sino 19 cell persistence (Nos. 1, 3, 27, and 38). Nine patients (Nos. 2, 4, 7, 13, 16, 26, 28, 33, and 34) failed to achieve CR/CRi (indicated by NR), however, Sino 19 cell was detected in their blood from day 1 to day 60 after the infusion. Two patients (Nos. 8 and 18) who did not bridge to allo-HSCT maintained continue remission and survived for more than 1 year after the Sino 19 cell loss. b The panel shows the detection of B cell in a patient before and after the infusion of Sino 19 cells; B-cell aplasia was defined as CD45 strong and CD19-positive (CD19⁺CD45⁺⁺) B cells <2% in lymphocyte gate; recovery was defined as ≥2%. c The panel shows that the persistence time of Sino 19 cells positively well correlated with the duration of B cell aplasia in patients who achieved CR/CRi without bridging to allo-HSCT (p = 1.08e−7, R = 0.884, by using two-sided Pearson correlation coefficient). Source data of (a) and (c) are provided as a Source Data file or available at https://doi.org/10.6084/m9.figshare.13136078.v1.